| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Banyu Tsukuba Research Institute in collaboration with Merck Research Laboratories, Okubo 3, Tsukuba 300-33, Japan
A new indolocarbazole antitumor agent, NB-506 [6-N-formylamino-12,13-dihydro-1,11-dihydroxy-13-(ß-D-glucopyranosyl)-5H-indolo[2,3-a]pyrrolo[3,4-c]carbazole-5,7(6H)-dione], enhanced the DNA cleavage catalyzed by HeLa S3 topoisomerase I at 0.01 µM but not the cleavage by topoisomerase II at 300 µM. It also caused single-strand DNA breakage in intact cells at 0.08 µM and more. Unlike the known topoisomerase I inhibitor camptothecin, NB-506 intercalated with DNA. However, the binding affinity to DNA and the inhibition against DNA polymerase 
and RNA polymerase II were marginal compared with those of Adriamycin or actinomycin D. NB-506 inhibited the growth of various tumor cell lines at two micromoles or less, and its cytotoxicity was found to be cell line selective. This selective cytotoxicity of NB-506 was not fully explained by the differences in topoisomerase I activity in these cell lines, but there was some relationship between the amount of NB-506 accumulated in these cell lines and its cytotoxicity toward them. In conclusion, NB-506 is a potent topoisomerase I poison, acting selectively on tumor cell lines accumulating NB-506.
1 To whom requests for reprints should be addressed.
Received 10/18/94. Accepted 1/16/95.
This article has been cited by other articles:
|
|
 |
|
  M. Facompre, C. Carrasco, P. Colson, C. Houssier, J. D. Chisholm, D. L. Van Vranken, and C. Bailly DNA Binding and Topoisomerase I Poisoning Activities of Novel Disaccharide Indolocarbazoles Mol. Pharmacol., November 1, 2002; 62(5): 1215 - 1227. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Takenaga, M. Ishii, T. Kamei, and T. Yasumori Structure-Activity Relationship in O-Glucuronidation of Indolocarbazole Analogs Drug Metab. Dispos., May 1, 2002; 30(5): 494 - 497. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Carrasco, M. Facompre, J. D. Chisholm, D. L. Van Vranken, W. D. Wilson, and C. Bailly DNA sequence recognition by the indolocarbazole antitumor antibiotic AT2433-B1 and its diastereoisomer Nucleic Acids Res., April 15, 2002; 30(8): 1774 - 1781. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. H. Woo, J. R. Vance, A. R. O. Marcos, C. Bailly, and M.-A. Bjornsti Active Site Mutations in DNA Topoisomerase I Distinguish the Cytotoxic Activities of Camptothecin and the Indolocarbazole, Rebeccamycin J. Biol. Chem., February 1, 2002; 277(6): 3813 - 3822. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Komatani, H. Kotani, Y. Hara, R. Nakagawa, M. Matsumoto, H. Arakawa, and S. Nishimura Identification of Breast Cancer Resistant Protein/Mitoxantrone Resistance/Placenta-Specific, ATP-binding Cassette Transporter as a Transporter of NB-506 and J-107088, Topoisomerase I Inhibitors with an Indolocarbazole Structure Cancer Res., April 1, 2001; 61(7): 2827 - 2832. [Abstract] [Full Text]
|
|
|
|
|
|
Y. Urasaki, G. S. Laco, P. Pourquier, Y. Takebayashi, G. Kohlhagen, C. Gioffre, H. Zhang, D. Chatterjee, P. Pantazis, and Y. Pommier Characterization of a Novel Topoisomerase I Mutation from a Camptothecin-resistant Human Prostate Cancer Cell Line Cancer Res., March 1, 2001; 61(5): 1964 - 1969. [Abstract] [Full Text]
|
|
|
|
|
|
Y. Urasaki, G. Laco, Y. Takebayashi, C. Bailly, G. Kohlhagen, and Y. Pommier Use of Camptothecin-resistant Mammalian Cell Lines to Evaluate the Role of Topoisomerase I in the Antiproliferative Activity of the Indolocarbazole, NB-506, and Its Topoisomerase I Binding Site Cancer Res., January 1, 2001; 61(2): 504 - 508. [Abstract] [Full Text]
|
|
|
|
|
|
T. Yoshinari, M. Ohkubo, K. Fukasawa, S.-i. Egashira, Y. Hara, M. Matsumoto, K. Nakai, H. Arakawa, H. Morishima, and S. Nishimura Mode of Action of a New Indolocarbazole Anticancer Agent, J-107088, Targeting Topoisomerase I Cancer Res., September 1, 1999; 59(17): 4271 - 4275. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Pollack, L. Young, J. Bilsland, N. Wilkie, S. Ellis, F. Hefti, H. Broughton, and S. Harper The Staurosporine-Like Compound L-753,000 (NB-506) Potentiates the Neurotrophic Effects of Neurotrophin-3 by Acting Selectively at the TrkA Receptor Mol. Pharmacol., July 1, 1999; 56(1): 185 - 195. [Abstract] [Full Text]
|
|
|
|
|
|
H. Komatani, M. Morita, N. Sakaizumi, K. Fukasawa, E. Yoshida, A. Okura, T. Yoshinari, and S. Nishimura A New Mechanism of Acquisition of Drug Resistance by Partial Duplication of Topoisomerase I Cancer Res., June 1, 1999; 59(11): 2701 - 2708. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Bailly, L. Dassonneville, P. Colson, C. Houssier, K. Fukasawa, S. Nishimura, and T. Yoshinari Intercalation into DNA Is Not Required for Inhibition of Topoisomerase I by Indolocarbazole Antitumor Agents Cancer Res., June 1, 1999; 59(12): 2853 - 2860. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Q. Fu, S.-W. Kim, H.-X. Chen, S. Grill, and Y.-C. Cheng Degradation of Topoisomerase I Induced by Topoisomerase I Inhibitors Is Dependent on Inhibitor Structure but Independent of Cell Death Mol. Pharmacol., April 1, 1999; 55(4): 677 - 683. [Abstract] [Full Text]
|
|
|
|
|
|
N. Takenaga, M. Ishii, S. Nakajima, T. Hasegawa, R. Iwasa, H. Ishizaki, and T. Kamei In Vivo Metabolism of a New Anticancer Agent, 6-N-formylamino-12,13-dihydro-1,11-dihydroxy-13-(beta -D-glucopyranosil)5H-indolo [2,3-a]pyrrolo [3,4-c]carbazole-5,7(6H)-dione (NB-506) in Rats and Dogs: Pharmacokinetics, Isolation, Identification, and Quantification of Metabolites Drug Metab. Dispos., February 1, 1999; 27(2): 205 - 212. [Abstract] [Full Text]
|
|
|
|
|
|
N. Takenaga, T. Hasegawa, M. Ishii, H. Ishizaki, S. Hata, and T. Kamei In Vitro Metabolism of a New Anticancer Agent, 6-N-formylamino-12,13-dihydro-1,11-dihydroxy-13-(beta -D-glucopyranosil)5H-indolo [2,3-a]pyrrolo [3,4-c]carbazole-5,7(6H)-dione (NB-506), in Mice, Rats, Dogs, and Humans Drug Metab. Dispos., February 1, 1999; 27(2): 213 - 220. [Abstract] [Full Text]
|
|
|
|
|
|
E. Labourier, J.-F. Riou, M. Prudhomme, C. Carrasco, C. Bailly, and J. Tazi Poisoning of Topoisomerase I by an Antitumor Indolocarbazole Drug: Stabilization of Topoisomerase I-DNA Covalent Complexes and Specific Inhibition of the Protein Kinase Activity Cancer Res., January 1, 1999; 59(1): 52 - 55. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Kohlhagen, K. D. Paull, M. Cushman, P. Nagafuji, and Y. Pommier Protein-Linked DNA Strand Breaks Induced by NSC 314622, a Novel Noncamptothecin Topoisomerase I Poison Mol. Pharmacol., July 1, 1998; 54(1): 50 - 58. [Abstract] [Full Text]
|
|
|
|
|
|
C. Bailly, P. Colson, C. Houssier, E. Rodrigues-Pereira, M. Prudhomme, and M. J. Waring Recognition of Specific Sequences in DNA by a Topoisomerase I Inhibitor Derived from the Antitumor Drug Rebeccamycin Mol. Pharmacol., January 1, 1998; 53(1): 77 - 87. [Abstract] [Full Text]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |
